21 results found.

Neutropenia Clinical Trial using HM10460A (45 æg/kg); HM10460A (135 æg/kg); HM10460A (270 æg/kg); Pegfilgrastim 6mg

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen.
HM10460A (45 æg/kg); HM10460A (135 æg/kg); HM10460A (270 æg/kg); Pegfilgrastim 6mg

Febrile Neutropenia, or Hematological Diseases Clinical Trial using Micafungin sodium; Itraconazole

Yonsei University - Recruiting 18 years to 65 years.
- A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases.
Micafungin sodium; Itraconazole

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Multidrug Resistance, Hematopoietic Stem Cell Transplantation, or Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Studies of the Human Microbiome in Clinical Center Patients.

Aplastic Anemia, Neutropenia, Pancytopenia, Anemia, or Thrombocyt Clinical Trial using Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia.
Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

Fanconi's Anemia, Anemia, Diamond Blackfan, Dyskeratosis Congenit Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study.

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-2 Clinical Trial using lipegfilgrastim; pegfilgrastim

Teva Pharmaceutical Industries - Recruiting 65 years to 85 years.
- A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulastar, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia.
lipegfilgrastim; pegfilgrastim

Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrh Clinical Trial using levofloxacin

Children's Oncology Group - Recruiting 6 Months to 21 years.
- A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT).
levofloxacin

Prostate Cancer Clinical Trial using CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Sanofi - Recruiting 18 years or older.
- A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context..
CABAZITAXEL (XRP6258); Prednisone; Ciprofloxacin; G-CSF (Granulocyte colony-stimulating factor)

Febrile Neutropenia Clinical Trial using Empirical antimicrobial treatment discontinuation; Standard empirical antimicrobial treatment discontinuation

Fundaci¢n P£blica Andaluza para la gesti¢n de la Investigaci¢n en Sevilla - Recruiting 18 years or older.
- Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia.
Empirical antimicrobial treatment discontinuation; Standard empirical antimicrobial treatment discontinuation

Neutropenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Natural History and Molecular Characterization of Benign Ethnic Neutropenia in Individuals of African Descent.

Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia, Neutropenia, Clinical Trial using Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Thomas Jefferson University - Recruiting 18 years or older.
- Compassionate Use of the CliniMACSr CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells.
Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Neutropenia, Sickle Cell Disease, Decitabine, or Fetal Hemoglobin Clinical Trial using Decitabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- An Extended Phase II Study of Decitabine in Subjects With High Risk Sickle Cell Disease.
Decitabine

Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskot Clinical Trial using 4 doses of abatacept; 6 doses of abatacept

Emory University - Recruiting N/A to 21 years.
- Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Disease: a Dose Assessment Pilot.
4 doses of abatacept; 6 doses of abatacept

Myelodysplastic Syndrome (MDS), or Severe Aplastic Anemia (SAA) Clinical Trial using Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 75 years.
- Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy.
Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

Anemia, Leukemia, or Neutropenia Clinical Trial using fludarabine phosphate; methotrexate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL).
fludarabine phosphate; methotrexate

Severe Combined Immunodeficiency (SCID), Immunodeficiency With Pr Clinical Trial using CD3/CD19 negative allogeneic hematopoietic stem cells

University of Pittsburgh - Recruiting 5 years to 40 years.
- Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors.
CD3/CD19 negative allogeneic hematopoietic stem cells

Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome Clinical Trial using sirolimus

Children's Hospital of Philadelphia - Recruiting 1 year to 30 years.
- Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series.
sirolimus

Anemia, Hematologic Neoplasm, Neutropenia, Pancytopenia, or Throm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols.

Febrile, Neutropenia, or Hematopoietic Stem Cell Transplantation Clinical Trial using Piperacillin-tazobactam combination product; Imipenem

Chinese PLA General Hospital - Recruiting 13 years to 65 years.
- A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation.
Piperacillin-tazobactam combination product; Imipenem

Invasive Fungal Infections, Invasive Aspergillosis, or Invasive F Clinical Trial using caspofungin as preemptive antifungal therapy

Federal University of Rio de Janeiro - Recruiting 18 years or older.
- Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index.
caspofungin as preemptive antifungal therapy